Trial Profile

A Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cilastatin/imipenem/relebactam (Primary) ; Linezolid; Piperacillin/tazobactam
Indications Bacterial infections; Nosocomial pneumonia; Ventilator associated pneumonia
Focus Adverse reactions; Registrational
Sponsors Merck Sharp & Dohme Corp.

01 Apr 2025 Results assessing Efficacy and safety of IMI/REL Vs piperacillin/tazobactam (PIP/TAZ) published in the International Journal of Infectious Diseases
19 Jul 2022 Status changed from active, no longer recruiting to completed.
26 Jun 2022 Planned End Date changed from 31 Oct 2022 to 31 Jul 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com